Get the Stockscreener App
0.00
100.00%
-0.0111
Virpax Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0111
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-12.07M
P/E Ratio:
0.00
EPS:
-10.6183
Net Cash Flow:
$-16.71M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-99.74%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.00 | 0 | 0 | -12.07M | -16.71M | -10.62 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax reports positive study results for pain management drug - MSN
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
BTAX Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
VRPX Stock Price and Chart — OTC:VRPX - TradingView
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Reports on Progress of Envelta™ - Business Wire
Business InsuranceMagazineVirpax Pharmaceuticals Announces Reverse Stock Split - FinancialContent
Virpax receives positive Probudur™ results for dose range study - TradingView
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MyChesCo
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
FinancialContentVirpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants - FinancialContent
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
User - The Chronicle-Journal
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Star Tribune - FinancialContent
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
Cap:
|
Volume (24h):